
    
      PURPOSE is a randomized double-blind placebo-controlled study. Main objective is to assess
      the effectivity of omega-3 fatty acid treatment in the prevention of psychosis. The primary
      outcome measure is the rate of transition to psychosis as determined through CAARMS. Subjects
      in the age range of 13-20 years with a higher chance of developing psychosis, as determined
      by the CAARMS, are treated for 6 months with omega-3 fatty acids or placebo. This study in
      conducted at 14 sites in 9 countries.
    
  